TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6763394
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose tobramycin
Study: 6763394
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose amikacin
Study: 6763394
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose amikacin
Study: 22772870
Drug: S-pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-pantoprazole 20 mg
Study: 17323787
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg (pretreatment)
Study: 17323787
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg (concomitant treatment)
Study: 17323787
Drug: Aspirin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (both treatments)
Study: 2754630
Drug: Nortriptyline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline treatment for seven weeks with plasma levels kept between 50‐180 ng/ml
Study: 865738
Drug: General inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: General inhalation anesthesia
Study: 865738
Drug: Analgesia and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesia and General inhalation anesthesia
Study: 12718225
Drug: Trimethazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethazidine (20 mg thrice a day)
Study: 11206600
Drug: sertraline, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline, 50 mg/day
Study: 11206600
Drug: sertraline, 100
Normalized name: Sertraline, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline, 100 mg/day
Study: 11206600
Drug: fluoxetine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoxetine, 20 mg/day
Study: 11206600
Drug: sertraline, 100
Normalized name: Sertraline, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline, 100 mg/day (after dose increase)
Study: 11206600
Drug: sertraline, 200
Normalized name: Sertraline, 200 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline, 200 mg/day (after dose increase)
Study: 11206600
Drug: fluoxetine, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoxetine, 40 mg/day (after dose increase)
Study: 9313279
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream with suggestion that it might help reduce needle pain
Study: 9313279
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream with no indication of purpose
Study: 9313279
Drug: Observer ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observer ratings for cream plus suggestion
Study: 9313279
Drug: Observer ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observer ratings for cream alone
Study: 25023055
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral prophylaxis
Study: 22613532
Drug: Anisodamine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisodamine (0.1 - 0.2 µg × kg(‐1)× min(‐1) intravenous infusion from PCI to 24 hours after PCI)
Study: 20220748
Drug: Silodosin 24
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin 24 mg
Study: 18224311
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg oral dose) with clarithromycin (800 mg/day)
Study: 18224311
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg oral dose) with fluvoxamine (50 mg/day)
Study: 18224311
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg oral dose) with placebo
Study: 12100205
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1 g daily (follow-up)
Study: 9589224
Drug: 20.7 mmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.7 mmol MgO daily for 30 days
Study: 9589224
Drug: 41.4 mmol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 41.4 mmol MgO daily for 30 days
Study: 8025966
Drug: Chemoembolization using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoembolization using ethiodized oil (Lipiodol) and anticancer agents (Mitomycin in 40 patients, DADH in 58 patients)
Study: 27861700
Drug: Cholecalciferol 4,000
Normalized name: CHOLECALCIFEROL 4,000UNIT CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 4,000 IU daily for 9 months
Study: 19858396
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² with cisplatin 50 mg/m² (arm A)
Study: 19858396
Drug: Gemcitabine 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,500 mg/m² at a fixed dose rate of 10 mg/m²/min (arm B)
Study: 19858396
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² with docetaxel 40 mg/m² (arm C)
Study: 19858396
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² with irinotecan 100 mg/m² (arm D)
Study: 14970134
Drug: Remifentanil by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil by bolus injection
Study: 11642083
Drug: Neoton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoton therapy
Study: 11642083
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (TLT) without neoton
Study: 11642083
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (TLT) with streptokinase preparations
Study: 11642083
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (TLT) with streptokinase preparations and neoton
Study: 21531706
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment after first seizure
Study: 8988885
Drug: Vaccine 1
Normalized name: TWINRIX vaccine 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine 1
Study: 8988885
Drug: Vaccine 2
Normalized name: RABIES VACCINE 2.5UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine 2
Study: 8988885
Drug: Vaccine 3
Normalized name: LYME DISEASE VACCINE 30MCG/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine 3
Study: 8233271
Drug: 500-mg naproxen
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg naproxen suppositories
Study: 21034476
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy (GDT) with individualized fluid replacement
Study: 18763691
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg HPP-containing tablets
Study: 18763691
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg HPP-containing tablets
Study: 18763691
Drug: 0% HPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% HPP control tablets
Study: 14602747
Drug: Phytoestrogen (114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogen (114 mg isoflavonoids)
Study: 10951436
Drug: deflazacort (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: deflazacort (0.9 mg/kg/day)
Study: 10951436
Drug: prednisone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone (0.75 mg/kg/day)
Study: 8797398
Drug: Albuterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (100 micrograms per puff, max 16 puffs)
Study: 8797398
Drug: Albuterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (100 micrograms per puff)
Study: 1474082
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg/kg iv)
Study: 6706302
Drug: Branched-chain enriched
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain enriched amino acid solution (BCAA, 80 gm per day)
Study: 6706302
Drug: Branched-chain enriched
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain enriched amino acid solution (BCAA)
Study: 31814710
Drug: Apatinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib as maintenance therapy following chemotherapy
Study: 31814710
Drug: Apatinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib as palliative following chemotherapy
Study: 31814710
Drug: Apatinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib alone as salvage therapy
Study: 29691947
Drug: Adolescent focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent focused therapy
Study: 27252412
Drug: 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μg GTL001 + imiquimod
Study: 27252412
Drug: 600 μg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μg GTL001 + placebo cream
Study: 22445475
Drug: Cockroft &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cockroft & Gault (C&G)
Study: 17680515
Drug: Sequential SV‐CABG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential SV‐CABG (seqSV‐CABG)
Study: 17169645
Drug: Periprostatic infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic infiltration of 6 mL 1% lidocaine
Study: 17169645
Drug: Periprostatic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic and apical infiltration: 4 mL 1% lidocaine at the prostate-seminal vesicle junction and 2 mL infiltration at the prostatic apex
Study: 12578924
Drug: Voice Treatment
Normalized name: Accu-Chek Voicemate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice Treatment (VT) using the Lee Silverman Voice Treatment method
Study: 12578924
Drug: Voice Treatment
Normalized name: Accu-Chek Voicemate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice Treatment (VT)
Study: 10494189
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy with autologous stem cell support
Study: 31776726
Drug: R-GEM-L (lenalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-GEM-L (lenalidomide + rituximab + methylprednisolone + gemcitabine)
Study: 27030499
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group (no IUD or steroids)
Study: 15611795
Drug: Sequential MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential MTX (200 mg m(‐2) i.v. on days 1 and 15) followed by FU (600 mg m(‐2) i.v. on days 2 and 16) and LV rescue (15 mg p.o. q 6 h x 6 doses)
Study: 15611795
Drug: 5-fluorouracil (370
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (370 mg m(‐2) i.v. bolus) preceded by leucovorin (100 mg m(‐2) i.v. bolus on days 1-5)
Study: 8481662
Drug: High-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine arabinoside
Study: 11587367
Drug: Incorporation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorporation of gemtuzumab zogamicin into treatment regimens
Study: 9144906
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg b.i.d.
Study: 16358396
Drug: Obese subjects
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obese subjects with or without binge-eating disorder in single-item meal (ice cream)
Study: 16358396
Drug: Non-obese controls
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-obese controls in single-item meal (ice cream)
Study: 16358396
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with bulimia nervosa (BN) in single-item meal (ice cream)
Study: 21915003
Drug: Infusion-site reactions
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion-site reactions (pain, erythema, swelling)
Study: 17163239
Drug: Bendroflumethiazide 1.25
Normalized name: bendroflumethiazide 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 1.25 mg/day and potassium chloride
Study: 17163239
Drug: Bendroflumethiazide 2.5
Normalized name: bendroflumethiazide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 2.5 mg/day and potassium chloride
Study: 14557093
Drug: Oral objective-structured
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral objective-structured clinical examination (OSCE) sessions (oral)
Study: 10746824
Drug: Glipizide (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (11 mg/day)
Study: 10746824
Drug: Glyburide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (10 mg/day)
Study: 6460474
Drug: Acne treatment
Normalized name: Acne Treatment
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acne treatment
Study: 31984445
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg D-cycloserine
Study: 21911655
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU of insulin
Study: 21911655
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of insulin
Study: 19444555
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride (0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.04 mg x kg(‐1) x min(‐1) infusion)
Study: 17578462
Drug: NaCl 0.9%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9%, 750 ml/m(2) body surface area (BSA)
Study: 17578462
Drug: hydroxyethylic starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyethylic starch 10%, 250 ml/m(2) BSA and NaCl 0.9%, 400 ml/m(2) BSA
Study: 17578462
Drug: dextran 10%,
Normalized name: Dextran 10%, Dextrose 5% Solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextran 10%, 250 ml/m(2) BSA and NaCl 0.9%, 300 ml/m(2) BSA
Study: 17578462
Drug: hypertonic sodium
Normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypertonic sodium chloride 7.2%/hyperoncotic hydroxyethylic starch 10%, 150 ml/m(2) BSA
Study: 17578462
Drug: hypertonic sodium
Normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypertonic sodium chloride 7.2%/hyperoncotic dextran 10%, 150 ml/m(2) BSA
Study: 9086315
Drug: NaCl (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (0.2 g/kg/day)
Study: 2007961
Drug: 30 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mmol/L alanine in WHO oral rehydration solution (ORS)
Study: 2007961
Drug: Standard WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard WHO oral rehydration solution (ORS)
Study: 6808838
Drug: Acyclovir 3
Normalized name: acyclovir 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 3 percent ophthalmic ointment
Study: 6808838
Drug: Trifluorothymidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluorothymidine 2 percent ointment
Study: 28040502
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PAD) with toluidine blue (0.1mg/mL) and LED lamp (635nm, 200mW/cm2) for 60s
Study: 28040502
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide therapy (Ca(OH)2) for two weeks
Study: 28040502
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between PAD and calcium hydroxide therapy
Study: 26335189
Drug: Homeopathic medication
Normalized name: homeopathic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medication (IFC group: Influcid®) for 7 days plus standard treatment (paracetamol, ambroxol, and/or oxymetazoline)
Study: 26335189
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST group: paracetamol, ambroxol, and/or oxymetazoline)
Study: 26335189
Drug: Homeopathic medication
Normalized name: homeopathic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic medication (IFC group: Influcid®)
Study: 28634002
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST group)
Study: 21624895
Drug: ICD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD patients without appropriate therapy
Study: 18972875
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of 40 mg pantoprazole
Study: 18972875
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of 40 mg pantoprazole
Study: 15756211
Drug: 5 ppm
Normalized name: silver nitrate 55 PPM TOPICAL GEL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ppm inhaled nitric oxide (iNO)
Study: 12504835
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins (folate, 10 mg; vitamin B-12, 200 microg; vitamin B-6, 20 mg/day)
Study: 12504835
Drug: L-arginine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (24 g/day)
Study: 8902440
Drug: Extraamniotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extraamniotic administration of ethacridine lactate (82 patients)
Study: 8902440
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin (PG) E2 gel (100 patients)
Study: 8902440
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of concentrated oxytocin (36 patients)
Study: 1879977
Drug: Verapamil-SR 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil-SR 240 mg twice daily
Study: 30980680
Drug: Carbapenem administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbapenem administration before or during chemotherapy
Study: 30980680
Drug: No carbapenem
Normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No carbapenem administration
Study: 28446297
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous mecobalamin (HDIME)
Study: 28446297
Drug: Bortezomib-based chemotherapy
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-based chemotherapy (Control)
Study: 24345428
Drug: Long-acting dihydrocodeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting dihydrocodeine tablets (DHC-Continus)
Study: 24345428
Drug: Short-acting dihydrocodeine
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting dihydrocodeine tablets
Study: 22943608
Drug: Radiotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy group (surgical treatment + adjuvant radiotherapy)
Study: 19954047
Drug: Intravenous levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous levofloxacin 500 mg once a day
Study: 9207281
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg/day during 14 days every 3 months)
Study: 9207281
Drug: Fluoride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride (50 mg/day, enteric-coated tablets)
Study: 3121288
Drug: Ensure (hourly)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ensure (hourly)
Study: 3121288
Drug: Ensure (4-hourly)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ensure (4-hourly)
Study: 3121288
Drug: PHT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT with Ensure (hourly) (B)
Study: 3121288
Drug: PHT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT with Ensure (4-hourly) (C)
Study: 29582543
Drug: Non-operative caries
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative caries treatment programme based on the Nexø method (NOCTP)
Study: 23724615
Drug: Topical calcipotriol
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriol and betamethasone dipropionate (combined regimen) for 4 weeks
Study: 23724615
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone valerate (monotherapy) for 4 weeks
Study: 18027038
Drug: granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: granisetron 3 mg i.v.
Study: 18027038
Drug: dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone 8 mg i.v.
Study: 10792122
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium sulphate (MgSO4)
Study: 9094893
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Fe once weekly
Study: 9094893
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Fe once weekly with anthelminthic treatment
Study: 28919067
Drug: Hepcidin quantification
Normalized name: Hepcidin-25
DrugBank: Hepcidin-25 (DB19226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepcidin quantification and treatment based on hepcidin levels
Study: 28919067
Drug: Hepcidin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepcidin treatment recommendations: IV iron when hepcidin <20μg/L; IV iron + erythropoietin when hepcidin 20-41μg/L
Study: 9505800
Drug: Spray-dried soya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-dried soya formula with 110 mg ascorbic acid/l
Study: 28183318
Drug: Multi-modal early
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal early oral nutrition (EON)
Study: 21813428
Drug: Narrative exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative exposure therapy (n = 29)